Detailed Results of Positive Phase 2 Trial of RPC1063 in Relapsing Multiple Sclerosis to be Presented at Late Breaker Session on September 13, 2014
Company to Host Investor Call and Webcast on September 15, 2014
SAN DIEGO, Sept. 10, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced that data from the Phase 2 portion of RADIANCE, the Company's Phase 2/3 trial of RPC1063 in Relapsing Multiple Sclerosis (RMS), will be reviewed in a late breaker oral podium presentation at MS Boston on September 13, 2014. MS Boston 2014 is a joint meeting of ACTRIMS and ECTRIMS, and is the largest meeting dedicated to multiple sclerosis to date. The data will be presented by Dr. Amit Bar-Or, M.D., Professor of Neurology and Associate in Microbiology and Immunology at McGill University and Scientific Director of the Clinical Research Unit at the Montreal Neurological Institute. Details are as follows:
|Date:||Saturday, September 13, 2014, 8:30am ET|
|Location:||Auditorium, John B. Hynes Veterans Memorial Convention Center|
|Session:||Session LB1: Late Breaking News|
|Title:||LB1.1 Phase 2 results of the RADIANCE trial: a randomized, double-blind, placebo-controlled trial of oral RPC1063 in relapsing multiple sclerosis|
In addition, the Receptos management team will host a teleconference and webcast to discuss the results in further detail on Monday, September 15 at 8:30am ET. The live call may be accessed by phone by calling (866) 757-6808 (domestic) or (760) 536-5211 (international), participant code 2249659. The webcast can be accessed live on the Investor Relations section of the Receptos website at www.receptos.com and will be archived for 14 days following the call. A replay of the call will be available by phone by calling (855) 859-2056, participant code 2249659.
RADIANCE is an accelerated design, randomized Phase 2/3 trial of RPC1063 for the treatment of Relapsing Multiple Sclerosis (RMS). The Phase 2 portion of RADIANCE was a randomized, double-blind, 24-week trial assessing the efficacy, safety and tolerability of two doses (0.5 mg and 1 mg) of oral RPC1063 against placebo in 258 patients with RMS across 77 sites in 13 countries completed in June 2014. The ongoing Phase 3 portion, a randomized, double-blind, double-dummy, two-year trial of 0.5 mg and 1 mg of oral RPC1063 against injectable interferon b‑1a (Avonex®) in 1,200 patients with RMS in 21 countries, began enrollment in December 2013 and is expected to be completed in 2017.
Receptos is a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases. The Company's lead program, RPC1063, is a sphingosine 1-phosphate 1 receptor (S1P1R) small molecule modulator candidate for immune indications, including relapsing multiple sclerosis (RMS) and inflammatory bowel disease (IBD). The Company is also developing RPC4046, an anti-interleukin-13 (IL-13) antibody for an allergic/immune-mediated orphan disease, eosinophilic esophagitis (EoE).
CONTACT: Media and Investor Contact: Graham K. Cooper Chief Financial Officer, Receptos (858) 652-5708 firstname.lastname@example.orgSource:Receptos, Inc